In the past few years, the immune checkpoint inhibitors (ICIs), which target the programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) axis, have led to a long-lasting response in some patients with NSCLC by prompting the exhausted tumor infiltrating lymphocytes [11]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.